287 related articles for article (PubMed ID: 15703823)
1. Natural killer cells play a role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro.
Kijima M; Saio M; Oyang GF; Suwa T; Miyauchi R; Kojima Y; Imai H; Nakagawa J; Nonaka K; Umemura N; Nishimura T; Takami T
Int J Oncol; 2005 Mar; 26(3):679-84. PubMed ID: 15703823
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 augmented activation of tumor associated macrophage plays the main role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro.
Ouyang GF; Saio M; Suwa T; Imai H; Nakagawa J; Nonaka K; Umemura N; Kijima M; Takami T
Int J Oncol; 2006 May; 28(5):1201-8. PubMed ID: 16596236
[TBL] [Abstract][Full Text] [Related]
3. Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.
Kurosawa S; Harada M; Matsuzaki G; Shinomiya Y; Terao H; Kobayashi N; Nomoto K
Immunology; 1995 Jun; 85(2):338-46. PubMed ID: 7642226
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis.
Kundu N; Fulton AM
Cell Immunol; 1997 Aug; 180(1):55-61. PubMed ID: 9316639
[TBL] [Abstract][Full Text] [Related]
5. Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity.
Abdel-Wahab ZA; Osanto S; Darrow TL; Barber JR; Vervaert CE; Gangavalli R; McCallister TJ; Seigler HF
Cancer Gene Ther; 1994 Sep; 1(3):171-9. PubMed ID: 7621248
[TBL] [Abstract][Full Text] [Related]
6. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor effects of dendritic and tumor cell fusions are not dependent on expression of MHC class I and II by dendritic cells.
Takagi Y; Kikuchi T; Niimura M; Ohno T
Cancer Lett; 2004 Sep; 213(1):49-55. PubMed ID: 15312683
[TBL] [Abstract][Full Text] [Related]
8. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
9. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.
Rodríguez T; Méndez R; Del Campo A; Jiménez P; Aptsiauri N; Garrido F; Ruiz-Cabello F
BMC Cancer; 2007 Feb; 7():34. PubMed ID: 17319941
[TBL] [Abstract][Full Text] [Related]
10. Protection against natural killer cells by interferon-gamma treatment of K562 cells cannot be explained by augmented major histocompatibility complex class I expression.
Nishimura M; Mitsunaga S; Akaza T; Mitomi Y; Tadokoro K; Juji T
Immunology; 1994 Sep; 83(1):75-80. PubMed ID: 7821970
[TBL] [Abstract][Full Text] [Related]
11. Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence.
Yoshimura K; Hazama S; Iizuka N; Yoshino S; Yamamoto K; Muraguchi M; Ohmoto Y; Noma T; Oka M
Cancer Gene Ther; 2001 Jan; 8(1):9-16. PubMed ID: 11219497
[TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma upregulates the susceptibility of human neuroblastoma cells to interleukin-2-activated natural killer cells.
Handgretinger R; Kimmig A; Lang P; Daurer B; Kuci S; Bruchelt G; Treuner J; Niethammer D
Nat Immun Cell Growth Regul; 1989; 8(4):189-96. PubMed ID: 2507905
[TBL] [Abstract][Full Text] [Related]
13. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model.
Ma D; Luyten GP; Luider TM; Niederkorn JY
Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):435-41. PubMed ID: 7843912
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-10 reduces natural killer sensitivity and downregulates MHC class I expression on H-ras-transformed cells.
Tsuruma T; Yagihashi A; Torigoe T; Sato N; Kikuchi K; Watanabe N; Hirata K
Cell Immunol; 1998 Mar; 184(2):121-8. PubMed ID: 9630838
[TBL] [Abstract][Full Text] [Related]
15. The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role.
Schneeberger A; Koszik F; Schmidt W; Kutil R; Stingl G
J Immunol; 1999 Jun; 162(11):6650-7. PubMed ID: 10352282
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of tumoricidal NK and NK T cell activities by MHC Kb molecules expressed on Th2-type gammadelta T and alphabeta T cells coinfiltrating in early B16 melanoma lesions.
Seo N; Tokura Y; Furukawa F; Takigawa M
J Immunol; 1998 Oct; 161(8):4138-45. PubMed ID: 9780186
[TBL] [Abstract][Full Text] [Related]
17. Dissimilar anti-tumour reactions induced by tumour cells engineered with the interleukin-2 or interleukin-15 gene in nude mice.
Di Carlo E; Meazza R; Basso S; Rosso O; Comes A; Gaggero A; Musiani P; Santi L; Ferrini S
J Pathol; 2000 Jun; 191(2):193-201. PubMed ID: 10861581
[TBL] [Abstract][Full Text] [Related]
18. Absence of major histocompatibility complex class I on neural stem cells does not permit natural killer cell killing and prevents recognition by alloreactive cytotoxic T lymphocytes in vitro.
Mammolenti M; Gajavelli S; Tsoulfas P; Levy R
Stem Cells; 2004; 22(6):1101-10. PubMed ID: 15536199
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18.
Nagai H; Hara I; Horikawa T; Fujii M; Kurimoto M; Kamidono S; Ichihashi M
Cancer Invest; 2000; 18(3):206-13. PubMed ID: 10754989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
